Article

HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

Department of Epidemiology, Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA.
Journal of Thrombosis and Haemostasis (Impact Factor: 5.55). 06/2004; 2(5):700-1. DOI: 10.1111/j.1538-7836.2004.00696.x
Source: PubMed
Download full-text

Full-text

Available from: Carine J M Doggen, Aug 21, 2015
0 Followers
 · 
75 Views
  • Source
    • "Beyond platelets, statins may inhibit plasmatic pathways of thrombus formation (Undas et al., 2005) and may affect fibrinolytic pathways (Bourcier and Libby, 2000). The first strong evidence of potential association between statin administration and reduced risk of thromboembolism has come from a case control study in postmenopausal women (Doggen et al., 2004) in which statin administration was associated with a slightly lower risk of venous thrombosis. Other case control studies (Lacut et al., 2004; Ramcharan et al., 2009; Sørensen et al., 2009) have also shown reduction in the risk of venous thrombosis ranging from 26 to 58%. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Statins, among the most commonly prescribed drugs worldwide, are cholesterol-lowering agents used to manage and prevent cardiovascular and coronary heart diseases. Recently, a multifaceted action in different physiological and pathological conditions has been also proposed for statins, beyond anti-inflammation and neuroprotection. Statins have been shown to act through cholesterol-dependent and -independent mechanisms and are able to affect several tissue functions and modulate specific signal transduction pathways that could account for statin pleiotropic effects. Typically, statins are prescribed in middle-aged or elderly patients in a therapeutic regimen covering a long life span during which metabolic processes, aging, and concomitant novel diseases, including cancer, could occur. In this context, safety, toxicity, interaction with other drugs, and the state of health have to be taken into account in subjects treated with statins. Some evidence has shown a dichotomous effect of statins with either cancer-inhibiting or -promoting effects. To date, clinical trials failed to demonstrate a reduced cancer occurrence in statin users and no sufficient data are available to define the long-term effects of statin use over a period of 10 years. Moreover, results from clinical trials performed to evaluate the therapeutic efficacy of statins in cancer did not suggest statin use as chemotherapeutic or adjuvant agents. Here, we reviewed the pharmacology of the statins, providing a comprehensive update of the current knowledge of their effects on tissues, biological processes, and pathological conditions, and we dissected the disappointing evidence on the possible future use of statin-based drugs in cancer therapy.
    Pharmacological reviews 11/2011; 64(1):102-46. DOI:10.1124/pr.111.004994 · 18.55 Impact Factor
  • Source
Show more